Home › Targets › CD38
Radioligand therapy target profile

CD38: IHC Expression in Cancer and Radioligand Target Profile

CD38 molecule · Ensembl ENSG00000004468 · Data updated 2026-11-09

CD38, CD38 molecule, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CD38 staining is highest in prostate cancer (17% of samples positive), thyroid cancer (25% of samples positive) and lymphoma (8% of samples positive). Clinical status: FDA-approved drug (any modality), with 3 active clinical trials.

Is CD38 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze CD38 free
LocalizationCell-Surface
Top cancer (IHC)Prostate Cancer
InternalizationNot assessed
Clinical stageFDA-approved drug (any modality)
Active trials3
Cancer association (Open Targets)0.66

Is CD38 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

CD38 IHC staining by cancer type

Protein expression of CD38 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Prostate Cancer0.11Low17%
Thyroid Cancer0.08Low25%
Lymphoma0.08Low8%
Testicular Cancer0.07Low20%
Liver Cancer0.03Low9%
Breast Cancer0.03Low8%
Cervical Cancer0.03Low8%

Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, melanoma, kidney cancer, bladder cancer, neuroendocrine tumors, lung cancer, pancreatic cancer, gastric cancer, endometrial cancer, glioma.

Is CD38 internalized?

Nuclens has not yet extracted internalization evidence for CD38. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

CD38 clinical trials

FDA-approved drug (any modality). 3 active trials reference CD38 (ClinicalTrials.gov, accessed 2026-11-09).

NCT05995041 · NCT03222674 · NCT04016129

CD38 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CD38 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

CD38 gene essentiality (DepMap)

CRISPR knockout effect across 1253 cancer cell lines: 0.03 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related prostate cancer radioligand targets

PSMA (FOLH1) · HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · FAP · B7-H3 (CD276) · STEAP2

See all radioligand therapy targets in prostate cancer.

See how CD38 ranks against 15,000 targets for your indication.

Analyze CD38 free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is CD38 the right target for your program? · 5 free analyses, no card Analyze CD38 free